Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Linda Pao

Neurology Jupiter, FL Medical Doctor

NPI 1417973827 CMS profile 245322

601 University Blvd, Suite 102 101, Jupiter, FL 33458

Open in the dashboard

General payments

$38,240

714 records reported · program years 2019–2025

Research payments

$153

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,106,604 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Linda Pao of Jupiter, FL is reported in the CMS Open Payments database as having received $38,240 across 714 general payments and $153 in research payments paid to them. Separately, studies naming them as principal investigator received $3,106,604 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,100 16
2024 General $2,272 21
2023 General $3,810 10
2023 Research $153 1
2022 General $2,952 132
2021 General $3,592 194
2020 General $2,233 122
2019 General $4,281 219

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Linda Pao
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Linda Pao were reported at $19,100. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Linda Pao Neurology median Middle half National median
2019 $4,281 $474 $118–$2,177 $163
2020 $2,233 $367 $82–$2,309 $114
2021 $3,592 $438 $104–$2,547 $132
2022 $2,952 $442 $103–$2,388 $149
2023 $3,810 $464 $119–$2,312 $160
2024 $2,272 $468 $119–$2,323 $164
2025 $19,100 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $17,613 7 payments
  2. Eisai Inc. $3,725 12 payments
  3. Merck Sharp & Dohme Corporation $2,136 17 payments
  4. Novartis Pharmaceuticals Corporation $1,139 67 payments
  5. E.R. Squibb & Sons, L.L.C. $1,019 7 payments
  6. Biogen, Inc. $966 33 payments
  7. EMD Serono, Inc. $810 33 payments
  8. Genzyme Corporation $734 30 payments
  9. Lilly USA, LLC $713 31 payments
  10. AbbVie, Inc. $693 51 payments
  11. Other $8,691 426 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,509 682 payments
  2. Travel and Lodging $13,627 13 payments
  3. Consulting Fee $8,835 3 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $251 14 payments
  5. Education $17 2 payments
Products named General payments · program years 2019–2025
  1. Leqembi $3,627 7 payments
  2. KESIMPTA $619 37 payments
  3. AIMOVIG $618 29 payments
  4. BOTOX $571 44 payments
  5. GOCOVRI $477 29 payments
  6. RYTARY $442 21 payments
  7. EMGALITY $441 24 payments
  8. UBRELVY $401 33 payments
  9. NURTEC ODT $392 17 payments
  10. ADUHELM $362 13 payments
  11. Other $10,067 493 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $153 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

90

Median for Psychiatry & Neurology: 100

Drug cost

$8,784

Median for Psychiatry & Neurology: $2,986

Branded share of claims

46.7%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 18 $5,825
Rasagiline Mesylate Generic 12 $1,708
Carbidopa-Levodopa Carbidopa/Levodopa Brand 12 $685
Venlafaxine Hcl Generic 12 $310
Pramipexole Dihydrochloride Pramipexole Di-Hcl Brand 12 $99
Zolpidem Tartrate Generic 12 $92
Rosuvastatin Calcium Generic 12 $65

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Leqembi
  • Eisai Inc. $125
$125 — —
KISUNLA
  • Lilly USA, LLC $123
$123 — —
APONVIE
  • Heron Therapeutics, Inc. $61
$61 — —
MOUNJARO
  • Lilly USA, LLC $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

715 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record